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Letter
Doenyas-Barak et al. concluded recently in Critical Care
that with similar high lactate levels (>10 mmol/L) the
prognosis of metformin users compared with non-users
was favorable during admission to the emergency de-
partment with septic shock (in-hospital mortality, 57 %
versus 88 %, P < 0.001) [1]. This observation and similar
findings reported previously are suggestive of a role for
metformin as a lactate generation amplifier [2, 3]. How-
ever, in this study, causality cannot be proven, since
without metformin concentration measurements a dose-
response analysis is not possible.
Despite the dramatic clinical presentation of metfor-
min-associated lactic acidosis (MALA), this study also
underlines the fact that its prognosis is better than
that of similarly severe lactic acidosis of other origins
[1, 4]. With an incidence of approximately 5 cases
per 100,000 patient-years, MALA is considered an ex-
ceedingly rare complication of chronic metformin
therapy [5]. Metformin is excreted unchanged by the
kidneys, predisposing patients with renal insufficiency
to the development of MALA. Several authors suggest
that the inclusion of renal impairment as a contra-
indication for metformin use should be reconsidered,
and this may increase the number of patients at risk
for developing MALA [5].
The findings reported in this study shed new light on
our current understanding of the impact of metformin on
lactate production. Given the large difference in mortality
between the two groups, it can be concluded that the
prognostic value of lactate is largely altered by metformin
use in patients presenting with shock. Evidently, a rela-
tively small sample size of patients (44 metformin users
and 118 non-users) is sufficient to observe differences
of such a magnitude in survival. Although the effect
may not be as pronounced as in the present study, we be-
lieve that metformin may also elevate lactate levels in pa-
tients presenting with less severe lactic acidosis [1, 2].
Therefore, a study comparing the prognosis of critically ill
metformin users with non-users in a large matched cohort
based on increasing lactate levels seems useful.
Because the effect of metformin on lactate levels in
such a population may not be immediately obvious,
we suspect that hyperlactatemia partly induced by
metformin is often not considered by physicians car-
ing for patients presenting with critical conditions.
This study might therefore have identified only the
tip of the iceberg regarding the effect of metformin
on lactate levels. For clinicians to be able to identify
and treat MALA in a more timely manner, lactate
levels should always be measured in the emergency
department or even in the prehospital setting.
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The main finding of our study was that patients
under metformin treatment with severe lactic acidosis
and septic shock have better prognosis than patients
without metformin treatment [1]. The difference can
be attributed to metformin accumulation, representing
MALA, and not the severity of the sepsis. In such cases,
the blood level of metformin would be expected to be
high. However, the difference between the groups may
also represent a metformin-related protective effect, in
which case the blood level of metformin would not neces-
sarily be high. Thus, lack of knowledge regarding
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circulating metformin levels is indeed a limitation of the
present study. Nonetheless, it is clear that severe lactic
acidosis under metformin treatment should be regarded
as a different entity. Thus, we agree that subclinical
MALA may be uncovered (or exposed) in some patients if
larger populations are evaluated and if blood lactate is
measured in all metformin users.
Posma et al. express concern that the low incidence of
MALA may change if renal failure as a contraindication
is reconsidered [6]. However, in the present cohort,
acute rather than chronic renal failure was associated
with MALA [1]. Metformin accumulates in patients with
renal failure, and its plasma level was found to be in
good correlation with renal function [7]. Thus, low-dose
metformin treatment in patients with stable chronic renal
failure may be safe. However, acute renal failure may pose
the risk of acute metformin accumulation and lactic acid-
osis [8]. Thus, the risk for acute renal failure should always
be considered before prescribing metformin.
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